General News Regulated OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices EN November 9, 2020
General News Regulated Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer EN October 13, 2020
General News Invitation OXURION R&D Investor Day – Virtual 15 October 2020 at 5.30pm CET/ 11.30am ET EN October 8, 2020
General News Save the date: Oxurion to host Virtual R&D Investor Day on 15 October 2020 EN October 5, 2020
General News Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4 EN September 29, 2020
General News Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference EN September 14, 2020
General News Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September EN September 11, 2020
General News Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) EN September 1, 2020
General News Regulated Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference EN February 9, 2020
General News Regulated Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference EN February 5, 2020
General News Regulated Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME EN January 7, 2020